Sophia Genetics SA Form 4 insider transactions

SOPHiA GENETICS SA Chief Medical Officer, Philippe Menu, reported a sale of 608 ordinary shares for $4.6059 each, executed under a Rule 10b5-1(c) trading plan.

Daan van Well, Chief Legal Officer of SOPHiA GENETICS SA, sold 684 ordinary shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

SOPHIA GENETICS SA reports that Chief People Officer Manuela Valente sold 380 ordinary shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

SOPHiA GENETICS SA reports that Chief Sales Officer Kevin Puylaert sold 33 ordinary shares to cover tax obligations related to vested restricted stock units.

Director Kathy L. Hibbs reported a sale of 7,508 ordinary shares of SOPHiA GENETICS SA under a pre-arranged trading plan.

Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, reported a sale of 5,000 ordinary shares for $4.6689 per share, executed under a Rule 10b5-1 trading plan.

SOPHiA GENETICS CEO Jurgi Camblong reported a sale of 8,500 ordinary shares for $5.0872 per share, executed under a Rule 10b5-1 trading plan.

SOPHIA GENETICS SA reports a Form 4 filing detailing a transaction by Chief Medical Officer Philippe Menu, involving the sale of 5,000 ordinary shares.

Chief Scientific Officer Zhenyu Xu sold 600 ordinary shares of SOPHiA GENETICS SA under a pre-arranged 10b5-1 trading plan.

CEO Jurgi Camblong sold 60,602 shares of SOPHiA GENETICS to cover tax obligations related to RSU vesting.

Chief Medical Officer Philippe Menu sold 1,600 shares of SOPHiA GENETICS SA as part of a pre-arranged trading plan.

President Ross Muken sold 2,800 shares of SOPHiA GENETICS to cover tax withholding obligations related to RSU vesting.

SOPHIA GENETICS SA reports that Chief Legal Officer Daan van Well sold 2,400 ordinary shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

SOPHIA GENETICS SA reports that Chief Scientific Officer Zhenyu Xu sold shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

SOPHiA GENETICS SA CEO Jurgi Camblong reports sales of company shares totaling over 12,000 units, executed under a pre-arranged trading plan.

SOPHIA GENETICS SA reports insider Muken Ross sold 3,687 ordinary shares on April 10, 2026, and 4,442 ordinary shares on April 13, 2026, as part of a pre-arranged trading plan.

SOPHiA GENETICS SA Chief Medical Officer, Philippe Menu, reported transactions involving the sale of ordinary shares, executed under a Rule 10b5-1(c) trading plan.

SOPHiA GENETICS SA CEO Jurgi Camblong sold a total of 4,750 ordinary shares to cover tax obligations related to vested restricted stock units, as disclosed in a Form 4 filing.

SOPHIA GENETICS SA reports that President Ross Muken sold shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

SOPHIA GENETICS SA reports that Chief Scientific Officer Zhenyu Xu sold shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

SOPHiA GENETICS SA Chief Medical Officer, Philippe Menu, reported transactions involving the sale of ordinary shares to cover tax obligations.

Manuela Valente, Chief People Officer at SOPHiA GENETICS SA, sold 3,824 ordinary shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

Daan Van Well, Chief Legal Officer of SOPHiA GENETICS SA, sold a total of 4,849 ordinary shares across two transactions to cover tax obligations related to vested restricted stock units.

SOPHIA GENETICS SA reports that Chief Financial Officer George Cardoza sold 1,403 ordinary shares to cover tax obligations related to vested restricted stock units.

SOPHiA GENETICS SA Chief Medical Officer, Philippe Menu, reported the sale of ordinary shares valued at approximately $13,130 to cover tax withholding obligations.

SOPHiA GENETICS SA reports that Chief Sales Officer Kevin Puylaert sold shares to cover tax obligations related to vested restricted stock units.

SOPHIA GENETICS SA reports that Chief Legal Officer Daan van Well sold shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

SOPHIA GENETICS SA reports that President Ross Muken sold shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

Jurgi Camblong, CEO of SOPHiA GENETICS SA, reported the sale of 5,100 ordinary shares through two transactions executed on April 6 and 7, 2026, under a pre-established Rule 10b5-1 trading plan.

SOPHIA GENETICS SA files Form 4/A to amend prior reporting of beneficial ownership, correcting the number of ordinary shares held by Chief Legal Officer Daan van Well.